VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.6 EUR | -1.05% |
|
-5.02% | -7.62% |
| Apr. 30 | Vetoquinol: down after sales update | CF |
| Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
| Sales 2023 | 529M 570M | Sales 2024 * | 551M 593M | Capitalization | 1.12B 1.2B |
|---|---|---|---|---|---|
| Net income 2023 | 55M 59.18M | Net income 2024 * | 55M 59.18M | EV / Sales 2023 | 2.04 x |
| Net cash position 2023 | 130M 140M | Net cash position 2024 * | 183M 197M | EV / Sales 2024 * | 1.7 x |
| P/E ratio 2023 * |
20.3
x | P/E ratio 2024 * |
20.1
x | Employees | 2,497 |
| Yield 2023 |
0.83% | Yield 2024 * |
0.84% | Free-Float | 32.58% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.05% | ||
| 1 week | -5.02% | ||
| Current month | +0.32% | ||
| 1 month | -2.37% | ||
| 3 months | -7.62% | ||
| 6 months | +14.25% | ||
| Current year | -7.62% |
1 week
92.60
100.00
1 month
92.60100.20
Current year
92.60110.00
1 year
76.30110.00
3 years
76.30161.00
5 years
41.90161.00
10 years
32.10161.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01-04-01 | |
| Director of Finance/CFO | 59 | - | |
Philippe Gruet
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Étienne Frechin
BRD | Director/Board Member | 86 | 62-07-01 |
| Chief Executive Officer | 55 | 01-04-01 | |
Philippe Arnold
BRD | Director/Board Member | 83 | 07-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 94.6 | -1.05% | 668 |
| 24-05-02 | 95.6 | +1.38% | 2,937 |
| 24-04-30 | 94.3 | -4.26% | 9,621 |
| 24-04-29 | 98.5 | -1.10% | 2,255 |
| 24-04-26 | 99.6 | +1.63% | 1,805 |
Real-time Euronext Paris, May 03, 2024 at 11:35 am EDT
More quotes
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-05-27
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
94.6
EUR
Average target price
105.7
EUR
Spread / Average Target
+11.70%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.62% | 1.21B | |
| -9.19% | 6.67B | |
| +24.75% | 3.7B | |
| -1.11% | 3.21B | |
| +6.08% | 1.52B | |
| -15.13% | 1.37B | |
| -25.63% | 1.24B | |
| -10.84% | 1.17B | |
| -.--% | 1.05B | |
| -7.07% | 832M |
- Stock Market
- Equities
- VETO Stock
